Aeterna Zentaris Names New CEO

Aeterna Zentaris (NASDAQ: AEZS  ) has made a significant change in its executive suite and boardroom. David Dodd is now the company's chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the reasons for the succession.

Dodd has been in the pharmaceutical and biotech industries for more than 35 years. He was CEO and chairman of BioReliance, now a unit of Sigma-Aldrich. He also served in various executive capacities for companies such as Serologicals (now a subsidiary of Millipore) and Solvay Pharmaceuticals, among other prominent firms in the industry.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2364242, ~/Articles/ArticleHandler.aspx, 4/21/2014 6:40:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement